Among them, we focused on arsenic trioxide (ATO), a widely used chemotherapeutic agent for treating acute promyelocytic leukemia (APL), since it activates TFEB [32], increases lysosomal activity [33] and the accumulation of acidic vesicles [34], and inhibits OXPHOS [35]. This evidence concerns the gene TFEB and acute promyelocytic leukemia.